Xilio Therapeutics, Inc. Cash and Restricted Cash
Xilio Therapeutics, Inc. (XLO) had Cash and Restricted Cash of $137.86 million as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-12
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $137.86M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $152.15M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $139.34M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $105.56M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2026-06-30 | $137.86M 10-Q · filed 2026-08-12 |
| 2026-03-31 | $152.15M 10-Q · filed 2026-05-12 |
| 2025-12-31 | $139.34M 10-Q · filed 2026-08-12 |
| 2025-09-30 | $105.56M 10-Q · filed 2025-11-13 |
| 2025-06-30 | $123.34M 10-Q · filed 2026-08-12 |
| 2025-03-31 | $90.86M 10-Q · filed 2026-05-12 |
| 2024-12-31 | $57.07M 10-Q · filed 2026-08-12 |
| 2024-09-30 | $63.03M 10-Q · filed 2025-11-13 |
| 2024-06-30 | $76.72M 10-Q · filed 2025-08-14 |
| 2024-03-31 | $36.74M 10-Q · filed 2025-05-08 |
| 2023-12-31 | $46.29M 10-K · filed 2026-03-23 |
| 2023-09-30 | $61.35M 10-Q · filed 2024-11-07 |
| 2023-06-30 | $76.96M 10-Q · filed 2024-08-08 |
| 2023-03-31 | $94.84M 10-Q · filed 2024-05-14 |
| 2022-12-31 | $121.95M 10-K · filed 2025-03-11 |
| 2022-09-30 | $140.70M 10-Q · filed 2023-11-09 |
| 2022-06-30 | $160.96M 10-Q · filed 2023-08-14 |
| 2022-03-31 | $178.51M 10-Q · filed 2023-05-09 |
| 2021-12-31 | $199.61M 10-K · filed 2024-04-01 |
| 2021-09-30 | $101.32M 10-Q · filed 2022-11-09 |
| 2021-06-30 | $121.85M 10-Q · filed 2022-08-09 |
| 2021-03-31 | $142.78M 10-Q · filed 2022-05-12 |
| 2020-12-31 | $20.79M 10-K · filed 2023-03-02 |
| 2020-09-30 | $33.48M 10-Q · filed 2021-12-02 |
| 2019-12-31 | $49.04M 10-K · filed 2022-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 |